Galmed Pharmaceuticals
GLMD
8 hedge funds and large institutions have $419K invested in Galmed Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 11 closing their positions.
0.08% more ownership
Funds ownership: 0.01% → 0.09% (+0.08%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
52% less capital invested
Capital invested by funds: $878K → $419K (-$459K)
53% less funds holding
Funds holding: 17 → 8 (-9)
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$115K |
| 2 |
Millennium Management
New York
|
+$27.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$432 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$58.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$17.4K |
| 3 |
VF
Virtu Financial
New York
|
-$13K |
| 4 |
WWM
Western Wealth Management
Golden,
Colorado
|
-$12.6K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$12K |
GLMD Hedge Fund Activity: Q2 2023 in Review
8 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2023, worth a combined $419K — down 52% from $878K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GLMD and 2 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $115K. The largest seller was Raymond James & Associates, exiting entirely with an estimated $58.9K sold.
- 8 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2023, down from 17 in Q1 2023.
- Funds reported $419K of Galmed Pharmaceuticals stock for Q2 2023, down 52% quarter-over-quarter.
- 2 funds opened new Galmed Pharmaceuticals positions in Q2 2023 and 11 closed out, a net change of -9 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2023 was Susquehanna International Group, an estimated $115K added.
- The largest Galmed Pharmaceuticals seller in Q2 2023 was Raymond James & Associates, an estimated $58.9K sold.
Based on aggregated 13F filings for Q2 2023.